Roelof van Ewijk: How should we move forward investigating new medicines in patients with refractory or recurrent osteosarcoma?
Quoting Roelof van Ewijk, Clinical research fellow in Princess Maxima Center for Pediatric Oncology, on LinkedIn:
”Now online! How should we move forward investigating new medicines in patients with refractory or recurrent osteosarcoma? Within the workpackage 3 of the Fight Osteosarcoma Through European Research (FOSTER) consortium on relapse trials we evaluated the design and outcome of nearly 20 years of phase II clinical trials. Results will inform our future trial design. Thank you for the collaboration with early career researchers in the FOSTER consortium and supervision by Nathalie Gaspar for this important project. All together aiming to improve our care and outcome for the patients with osteosarcoma.”
For the article click here.
Source: Roelof van Ewijk/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023